Gong Shen

689 total citations
21 papers, 516 citations indexed

About

Gong Shen is a scholar working on Infectious Diseases, Hepatology and Virology. According to data from OpenAlex, Gong Shen has authored 21 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 8 papers in Hepatology and 4 papers in Virology. Recurrent topics in Gong Shen's work include HIV/AIDS drug development and treatment (12 papers), Hepatitis C virus research (8 papers) and HIV Research and Treatment (4 papers). Gong Shen is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), Hepatitis C virus research (8 papers) and HIV Research and Treatment (4 papers). Gong Shen collaborates with scholars based in United States, China and New Zealand. Gong Shen's co-authors include Anita Mathias, Brian P. Kearney, S. Ramanathan, Anu Osinusi, John Ling, Polina German, Rita Humeniuk, Huyen Cao, Andrew Cheng and John G. McHutchison and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Gong Shen

17 papers receiving 503 citations

Peers

Gong Shen

EPIDE

HEPAT

VIROL

Michelle L. Ray United States

I Jiménez‐Nácher Spain

Rosa Ruiz-Valderas Spain

L. Trentini Italy

Olga M. Klibanov United States

Peter Langmann Germany

Neesha Rockwood United Kingdom

Amelia S. Petry United States

Tsunefusa Hayashida Japan

Charles Wakeford United States

Michelle L. Ray United States

Gong Shen

287 ×0.8

106 ×0.6

EPIDE

55 ×0.4

HEPAT

133 ×1.2

VIROL

91 ×1.1

Citations per year, relative to Gong Shen Gong Shen (= 1×) peers Michelle L. Ray

Countries citing papers authored by Gong Shen

Since Specialization

Citations

This map shows the geographic impact of Gong Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gong Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gong Shen more than expected).

Fields of papers citing papers by Gong Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gong Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gong Shen. The network helps show where Gong Shen may publish in the future.

Co-authorship network of co-authors of Gong Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Gong Shen. A scholar is included among the top collaborators of Gong Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gong Shen. Gong Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Jian, et al.. (2025). The differences in intestinal flora and metabolites between H-type hypertension and non-H-type hypertension. Journal of Translational Medicine. 23(1). 329–329.

Shen, Gong, Zimo Yang, Yi Lv, et al.. (2025). Development of Highly Selective Aldosterone Synthase Inhibitors. ACS Medicinal Chemistry Letters. 16(6). 1175–1181.

Humeniuk, Rita, Santosh Davies, Gong Shen, et al.. (2024). Clinical Pharmacokinetics and Safety of Remdesivir in Phase I Participants with Varying Degrees of Renal Impairment. Clinical Pharmacokinetics. 64(1). 67–78.

Abdelghany, Mazin, Amos Lichtman, Ran Duan, et al.. (2024). Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants. Clinical Pharmacology & Therapeutics. 116(5). 1231–1239. 3 indexed citations

Shelton, Mark, Gong Shen, Deqing Xiao, et al.. (2023). 538. Clinical Evaluation of Drug-drug Interactions with Remdesivir. Open Forum Infectious Diseases. 10(Supplement_2).

Hsueh, Chia‐Hsiang, et al.. (2021). Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects. Clinical and Translational Science. 15(2). 361–370. 8 indexed citations

Li, Cuiyun, Xiaojiao Li, Xiaoxue Zhu, et al.. (2020). Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. Clinical Therapeutics. 42(3). 448–457. 5 indexed citations

Humeniuk, Rita, Anita Mathias, Huyen Cao, et al.. (2020). Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects. Clinical and Translational Science. 13(5). 896–906. 177 indexed citations

Li, Xiaojiao, Hong Chen, Junqi Niu, et al.. (2018). Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in Healthy Chinese Subjects. Clinical Therapeutics. 40(9). 1556–1566. 4 indexed citations

10.

Mogalian, Erik, Luisa M. Stamm, Anu Osinusi, et al.. (2018). Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Clinical Infectious Diseases. 67(6). 934–940. 22 indexed citations

11.

Rodríguez‐Torres, M., Anuj Gaggar, Gong Shen, et al.. (2015). Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5). 543–549. 23 indexed citations

12.

Mogalian, Erik, Anita Mathias, Diana M. Brainard, et al.. (2015). P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. Journal of Hepatology. 62. S590–S591. 15 indexed citations

13.

Gaggar, Anuj, Claire Coeshott, David Apelian, et al.. (2014). Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study. Vaccine. 32(39). 4925–4931. 80 indexed citations

14.

Custodio, Joseph M., Martin S. Rhee, Gong Shen, et al.. (2014). Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment. Antimicrobial Agents and Chemotherapy. 58(5). 2564–2569. 21 indexed citations

15.

Ramanathan, S., Anita Mathias, Xuelian Wei, et al.. (2013). Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(1). 45–50. 34 indexed citations

16.

Shen, Gong, et al.. (2013). Investigation of the Pharmacokinetic Interaction between Ritonavir and CMDCK, a New Non-nucleoside Reverse Transcriptase Inhibitor. Drug Research. 63(5). 237–242. 2 indexed citations

17.

Mathias, Anita, John E. Hinkle, Gong Shen, et al.. (2008). Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 49(2). 156–162. 19 indexed citations

18.

Ramanathan, S., Gong Shen, John E. Hinkle, Jeffrey Enejosa, & Brian P. Kearney. (2007). Pharmacokinetics of Coadministered Ritonavir-Boosted Elvitegravir and Zidovudine, Didanosine, Stavudine, or Abacavir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(2). 160–166. 28 indexed citations

19.

Ramanathan, S., Gong Shen, Andrew Cheng, & Brian P. Kearney. (2007). Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137. JAIDS Journal of Acquired Immune Deficiency Syndromes. 45(3). 274–279. 54 indexed citations

20.

Thompson, Melanie, Harold A. Kessler, Joseph J. Eron, et al.. (2005). Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS. 19(15). 1607–1615. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact